Trial Profile

A Phase 2a Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of KAN-101 In Participants With Celiac Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KAN 101 (Primary)
Indications Coeliac disease
Focus Proof of concept; Therapeutic Use
Acronyms SynCeD
Sponsors Anokion; Kanyos Bio

Most Recent Events

10 Feb 2025 Status changed from active, no longer recruiting to completed.
19 Dec 2024 According to an Anokion media release, company announced the early completion of patient dosing in this study. and company expects topline data from this study in the first half of 2025.
06 Dec 2024 Planned End Date changed from 1 Jun 2025 to 13 Jan 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com